"10.1371_journal.pone.0027518","plos one","2011-11-23T00:00:00Z","Gerard J P van Westen; JÃ¶rg K Wegner; Peggy Geluykens; Leen Kwanten; Inge Vereycken; Anik Peeters; Adriaan P IJzerman; Herman W T van Vlijmen; Andreas Bender","Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands; Tibotec BVBA, Beerse, Belgium; Unilever Centre for Molecular Science Informatics, University of Cambridge, Cambridge, United Kingdom","Conceived and designed the experiments: GJPvW JKW API HWTvV AB. Performed the experiments: GJPvW PG LK IV AP. Analyzed the data: GJPvW JKW HWTvV AB. Contributed reagents/materials/analysis tools: GJPvW JKW PG LK IV AP API HWTvV AB. Wrote the paper: GJPvW JKW API HWTvV AB.","The authors have read the journals policy and have the following conflicts: The Non-Nucleoside Reverse Transcriptase Inhibitiros Etravirine and Rilpivirine are marketed drugs developed by Tibotec, one of the funders of the current study. GJPvW was funded by Tibotec BVBA and JKW, PG, LK, IV, AP and HWTvV are employees of this company. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2011","11","Gerard J P van Westen","GJPVW",9,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
